Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Changes in the TCRβ Repertoire and Tumor Immune Signature From a Cutaneous Melanoma Patient Immunized With the CSF-470 Vaccine: A Case Report.

Frontiers in immunology - 1 Jan 2018

Aris Mariana, Bravo Alicia Inés, Pampena María Betina, Blanco Paula Alejandra, Carri Ibel, Koile Daniel, Yankilevich Patricio, Levy Estrella Mariel, Barrio María Marcela, Mordoh José

Abstract excerpt

The allogeneic therapeutic vaccine CSF-470 has demonstrated a significant benefit over medium-dose IFNα2b in the distant metastasis-free survival for stages IIB-IIC-III cutaneous melanoma patients in a randomized phase II/III clinical trial (CASVAC-0401, NCT01729663). At the end of the 2-year CSF-470 immunization protocol, patient #006 developed several lung and one subcutaneous melanoma metastases; this later...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Vaccines
Share to Clinical Trials, Phase II as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials, Phase III as Topic

Share to Lymphocytes, Tumor-Infiltrating

Share to Melanoma, Cutaneous Malignant

Share to Randomized Controlled Trials as Topic

Share to Receptors, Antigen, T-Cell, alpha-beta

Share to Vaccination

Source

Open in PubMed Open full text

Identifiers

PMID: 29774030
DOI: 10.3389/fimmu.2018.00955
PMCID: PMC5944263

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Changes in the TCRβ Repertoire and Tumor Immune Signature From a Cutaneous Melanoma Patient Immunized With the CSF-470 Vaccine: A Case Report.PMID 29774030Read ↗

Combined TCR Repertoire Profiles and Blood Cell Phenotypes Predict Melanoma Patient Response to Personalized Neoantigen Therapy plus Anti-PD-1.Semantic proximity Read ↗

Advancements and Challenges in Personalized Therapy for BRAF-Mutant Melanoma: A Comprehensive ReviewSemantic proximity Read ↗

Targeted Therapy Given after Anti-PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity.Semantic proximity Read ↗

Getting personal in metastatic melanoma: neoantigen-based vaccines as a new therapeutic strategy.Semantic proximity Read ↗

Intratumoral administration of mRNA COVID-19 vaccine delays melanoma growth in miceSemantic proximity Read ↗

Antigen-specificity and DTIC before peptide-vaccination differently shape immune-checkpoint expression pattern, anti-tumor functionality and TCR repertoire in melanoma patientsSemantic proximity Read ↗

Tumor-infiltrating BRAFV600E-specific CD4+ T cells correlated with complete clinical response in melanomaSemantic proximity Read ↗

Neoantigen-specific CD4+ tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patientsSemantic proximity Read ↗

Evolution and modulation of antigen-specific T cell responses in melanoma patientsSemantic proximity Read ↗

PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumorsSemantic proximity Read ↗

Skin immunization for effective treatment of multifocal melanoma refractory to PD1 blockade and Braf inhibitors.Semantic proximity Read ↗

Characterization of the treatment-naive immune microenvironment in melanoma with BRAF mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.